Literature DB >> 24053345

Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Jens O Watzlawik1, Bharath Wootla, Meghan M Painter, Arthur E Warrington, Moses Rodriguez.   

Abstract

Immunoglobulins with germline sequences occur in invertebrates and vertebrates and are named naturally occurring autoantibodies (NAbs). NAbs may target foreign antigens, self- or altered self-components and are part of the normal immunoglobulin repertoire. Accumulating evidence indicates that naturally occurring antibodies can act as systemic surveillance molecules, which tag, damaged or stressed cells, invading pathogens and toxic cellular debris for elimination by the immune system. In addition to acting as detecting molecules, certain types of NAbs actively signal in different cell types with a broad range of responses from induction of apoptosis in cancer cells to stimulation of remyelination in glial cells. This review emphasizes functions and characteristics of NAbs with focus on remyelination-promoting mouse and human antibodies. Human remyelination-promoting NAbs are potential therapeutics to combat a wide spectrum of disease processes including demyelinating diseases like multiple sclerosis. We will highlight the identified glycosphingolipid (SL) antigens of polyreactive remyelination-promoting antibodies and their proposed mechanism(s) of action. The nature of the identified antigens suggests a lipid raft-based mechanism for remyelination-promoting antibodies with SLs as most essential raft components. However, accumulating evidence also suggests involvement of other antigens in stimulation of remyelination, which will be discussed in the text.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24053345      PMCID: PMC3909667          DOI: 10.1586/14737175.2013.835601

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  137 in total

1.  Proligodendroblast antigen (POA), a developmental antigen expressed by A007/O4-positive oligodendrocyte progenitors prior to the appearance of sulfatide and galactocerebroside.

Authors:  R Bansal; K Stefansson; S E Pfeiffer
Journal:  J Neurochem       Date:  1992-06       Impact factor: 5.372

2.  Effects of gangliosides on the expression of autoimmune demyelination in the peripheral nervous system.

Authors:  D Ponzin; A M Menegus; G Kirschner; M G Nunzi; M G Fiori; C S Raine
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

Review 3.  The natural autoantibodies system: between hypotheses and facts.

Authors:  S Avrameas; T Ternynck
Journal:  Mol Immunol       Date:  1993-08       Impact factor: 4.407

4.  Gangliosides improve the outcome of experimental allergic neuritis (EAN).

Authors:  B Oderfeld-Nowak; C Brosnan; A Cervone; J Oderfeld; R W Ledeen
Journal:  Acta Neurobiol Exp (Wars)       Date:  1990       Impact factor: 1.579

5.  In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination.

Authors:  J M Redwine; R C Armstrong
Journal:  J Neurobiol       Date:  1998-11-15

6.  Antisulfatide polyneuropathy: antibody-mediated complement attack on peripheral myelin.

Authors:  S Ferrari; M Morbin; E Nobile-Orazio; A Musso; G Tomelleri; L Bertolasi; N Rizzuto; S Monaco
Journal:  Acta Neuropathol       Date:  1998-12       Impact factor: 17.088

7.  Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  P J Dyck; P A Low; A J Windebank; S S Jaradeh; S Gosselin; P Bourque; B E Smith; K M Kratz; J L Karnes; B A Evans
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

8.  Ganglioside therapy of type I diabetes: enhancement of hyperglycemia in the low dose streptozotocin model.

Authors:  J Zielasek; H Kolb
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

9.  Comparison of the N-linked oligosaccharide structures of the two major human myelin glycoproteins MAG and P0: assessment of the structures bearing the epitope for HNK-1 and human monoclonal immunoglobulin M found in demyelinating neuropathy.

Authors:  D Burger; G Perruisseau; M Simon; A J Steck
Journal:  J Neurochem       Date:  1992-03       Impact factor: 5.372

10.  Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons.

Authors:  A Quattrini; M Corbo; S K Dhaliwal; S A Sadiq; A Lugaresi; A Oliveira; A Uncini; K Abouzahr; J R Miller; L Lewis
Journal:  J Neurol Sci       Date:  1992-10       Impact factor: 3.181

View more
  8 in total

1.  Characterization of the Antibody Response after Cervical Spinal Cord Injury.

Authors:  Antigona Ulndreaj; Apostolia Tzekou; Andrea J Mothe; Ahad M Siddiqui; Rachel Dragas; Charles H Tator; Emina E Torlakovic; Michael G Fehlings
Journal:  J Neurotrauma       Date:  2016-12-21       Impact factor: 5.269

2.  [New therapeutic strategies for remyelination in multiple sclerosis].

Authors:  D Kremer; H-P Hartung; M Stangel; P Küry
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 3.  Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.

Authors:  Caroline Grönwall; Gregg J Silverman
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

4.  Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth.

Authors:  Nevena Tzekova; André Heinen; Sebastian Bunk; Corinna Hermann; Hans-Peter Hartung; Birgit Reipert; Patrick Küry
Journal:  J Neuroinflammation       Date:  2015-05-29       Impact factor: 8.322

Review 5.  Remyelination Therapy in Multiple Sclerosis.

Authors:  Danielle E Harlow; Justin M Honce; Augusto A Miravalle
Journal:  Front Neurol       Date:  2015-12-10       Impact factor: 4.003

6.  Dose-dependent inhibition of demyelination and microglia activation by IVIG.

Authors:  Meike Winter; Christine Baksmeier; Julia Steckel; Sumanta Barman; Manish Malviya; Melanie Harrer-Kuster; Hans-Peter Hartung; Norbert Goebels
Journal:  Ann Clin Transl Neurol       Date:  2016-09-23       Impact factor: 4.511

7.  Natural Autoantibodies: An Undersugn Hero of the Immune System and Autoimmune Disorders-A Point of View.

Authors:  Stratis Avrameas; Haris Alexopoulos; Harry M Moutsopoulos
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

Review 8.  Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease.

Authors:  Agata Matejuk; Arthur A Vandenbark; Halina Offner
Journal:  Front Neurol       Date:  2021-05-31       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.